(Q45888026)

17 December 2017

title

Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity (English)

1 reference

17 December 2017

author

Ernst Wagner

8

1 reference

17 December 2017

author name string

Ralf Kircheis

1

1 reference

17 December 2017

Elinborg Ostermann

2

1 reference

17 December 2017

Markus F Wolschek

3

1 reference

17 December 2017

Cornelia Lichtenberger

4

1 reference

17 December 2017

Christine Magin-Lachmann

5

1 reference

17 December 2017

Lionel Wightman

6

1 reference

17 December 2017

Malgorzata Kursa

7

1 reference

17 December 2017

publication date

1 August 2002

1 reference

17 December 2017

published in

Cancer Gene Therapy

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

8

1 reference

17 December 2017

page(s)

673-680

1 reference

17 December 2017

Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Tumor necrosis factor (TNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Cachectin and tumour necrosis factor as two sides of the same biological coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Polyethylenimine-based intravenous delivery of transgenes to mouse lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Phase II clinical trial of high-dose recombinant human tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Microvascular permeability of normal and neoplastic tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

7 January 2021

Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

7 January 2021

Tumor necrosis factor causes microvascular protein leakage independently of neutrophils or mast cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

7 January 2021

Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700487

7 January 2021

Identifiers

DOI

10.1038/SJ.CGT.7700487

1 reference

17 December 2017

Dimensions Publication ID

1039031400

0 references

1 reference

17 December 2017